These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 19886836

  • 21. Antiretroviral therapies in women after single-dose nevirapine exposure.
    Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS, OCTANE A5208 Study Team.
    N Engl J Med; 2010 Oct 14; 363(16):1499-509. PubMed ID: 20942666
    [Abstract] [Full Text] [Related]

  • 22. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.
    AIDS; 2011 Mar 27; 25(6):F7-12. PubMed ID: 21412057
    [Abstract] [Full Text] [Related]

  • 23. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
    Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM.
    HIV Med; 2009 Aug 27; 10(7):397-406. PubMed ID: 19459986
    [Abstract] [Full Text] [Related]

  • 24. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A, AI266073 Study Group.
    J Acquir Immune Defic Syndr; 2009 Jun 01; 51(2):163-74. PubMed ID: 19357529
    [Abstract] [Full Text] [Related]

  • 25. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
    Betancor G, Garriga C, Puertas MC, Nevot M, Anta L, Blanco JL, Pérez-Elías MJ, de Mendoza C, Martínez MA, Martinez-Picado J, Menéndez-Arias L, Resistance Platform of the Spanish AIDS Research Network (ResRIS), Iribarren JA, Caballero E, Ribera E, Llibre JM, Clotet B, Jaén A, Dalmau D, Gatel JM, Peraire J, Vidal F, Vidal C, Riera M, Córdoba J, López Aldeguer J, Galindo MJ, Gutiérrez F, Álvarez M, García F, Pérez-Romero P, Viciana P, Leal M, Palomares JC, Pineda JA, Viciana I, Santos J, Rodríguez P, Gómez Sirvent JL, Gutiérrez C, Moreno S, Pérez-Olmeda M, Alcamí J, Rodríguez C, del Romero J, Cañizares A, Pedreira J, Miralles C, Ocampo A, Morano L, Aguilera A, Garrido C, Manuzza G, Poveda E, Soriano V.
    Retrovirology; 2012 Aug 13; 9():68. PubMed ID: 22889300
    [Abstract] [Full Text] [Related]

  • 26. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.
    HIV Clin Trials; 2015 Aug 13; 16(1):30-8. PubMed ID: 25777187
    [Abstract] [Full Text] [Related]

  • 27. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.
    J Acquir Immune Defic Syndr; 2014 Mar 01; 65(3):318-26. PubMed ID: 24525469
    [Abstract] [Full Text] [Related]

  • 28. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
    Andreatta K, Miller MD, White KL.
    J Acquir Immune Defic Syndr; 2013 Apr 01; 62(4):367-74. PubMed ID: 23187937
    [Abstract] [Full Text] [Related]

  • 29. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
    Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E.
    HIV Clin Trials; 2013 Apr 01; 14(5):204-15. PubMed ID: 24144897
    [Abstract] [Full Text] [Related]

  • 30. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D, Koontz D, Bazmi H, Bixby C, Jemsek J, Mellors JW.
    Antivir Ther; 2010 Apr 01; 15(3):437-41. PubMed ID: 20516563
    [Abstract] [Full Text] [Related]

  • 31. Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
    Pingen M, Nijhuis M, Mudrikova T, van Laarhoven A, Langebeek N, Richter C, Boucher CA, Wensing AM.
    J Antimicrob Chemother; 2015 Feb 01; 70(2):573-80. PubMed ID: 25261422
    [Abstract] [Full Text] [Related]

  • 32. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    Smith DE, Chan DJ, Maruszak H, Jeganathan S.
    Int J STD AIDS; 2011 Apr 01; 22(4):228-30. PubMed ID: 21515757
    [Abstract] [Full Text] [Related]

  • 33. CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention.
    Dorton BJ, Mulindwa J, Li MS, Chintu NT, Chibwesha CJ, Mbewe F, Frenkel LM, Stringer JS, Chi BH.
    BJOG; 2011 Mar 01; 118(4):495-9. PubMed ID: 21199294
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM, Cohen C, Dejesus E, Brinson C, Williams S, Yale KL, Ramanathan S, Wang MH, White K, Chuck SK, Cheng AK.
    HIV Clin Trials; 2013 Mar 01; 14(5):216-23. PubMed ID: 24144898
    [Abstract] [Full Text] [Related]

  • 35. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN, Gangakhedkar RR, Sen S, Hayatnagarkar SS, Tripathy SP, Paranjape RS.
    AIDS Res Hum Retroviruses; 2007 May 01; 23(5):682-5. PubMed ID: 17530993
    [Abstract] [Full Text] [Related]

  • 36. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
    Kuhn L, Sinkala M, Kankasa MP, Kasonde P, Thea DM, Aldrovandi GM.
    J Acquir Immune Defic Syndr; 2006 Jun 01; 42(2):260-2. PubMed ID: 16760802
    [No Abstract] [Full Text] [Related]

  • 37. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
    Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D, UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study.
    Antivir Ther; 2010 Jun 01; 15(2):203-11. PubMed ID: 20386075
    [Abstract] [Full Text] [Related]

  • 38. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr 01; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 39. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
    Pulido F, Fiorante S.
    Enferm Infecc Microbiol Clin; 2008 Jun 01; 26 Suppl 8():13-8. PubMed ID: 19195433
    [Abstract] [Full Text] [Related]

  • 40. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
    Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Frenkel L, Ndase P, Mugo NR, Celum C, Overbaugh J, Matsen FA, Partners PrEP Study Team.
    J Infect Dis; 2015 Apr 15; 211(8):1211-8. PubMed ID: 25587020
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.